NASDAQ:HRTX Heron Therapeutics Q3 2026 Earnings Date & Estimates $0.29 -0.01 (-2.41%) As of 12:39 PM Eastern This is a fair market value price provided by Massive. Learn more. Heron Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Heron Therapeutics in Q3 2026Heron Therapeutics is expected to post earnings of -$0.03 per share on revenue of $37.50 million. In the same quarter a year earlier Heron Therapeutics reported -$0.05 per share on revenue of $38.21 million. Heron Therapeutics last reported on August 10, 2026, posting -$0.03 per share and missing the -$0.0050 consensus estimate. Heron Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.03Expected Revenue$37.50 millionPrior-Year EPS-$0.05Prior-Year Revenue$38.21 millionExpected Revenue Growth-1.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.03 (Missed by -$0.0250)Last Quarter Revenue$37.67 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Heron Therapeutics Q3 2026 Earnings FAQ When does Heron Therapeutics report Q3 2026 earnings? Heron Therapeutics (NASDAQ:HRTX) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Heron Therapeutics' Q3 2026 earnings call? Heron Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Heron Therapeutics? Analysts expect Heron Therapeutics to post earnings of -$0.03 per share for Q3 2026. How much revenue is Heron Therapeutics expected to report? The consensus revenue estimate for Heron Therapeutics is $37.50 million for Q3 2026. Heron Therapeutics Earnings HeadlinesHeron Therapeutics consensus price target lowered by 20% to $2.04November 2 at 5:41 AM | msn.comHeron Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026October 26, 2026 | quiverquant.comQThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 3 at 1:00 AM | Porter & Company (Ad)Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026October 26, 2026 | markets.businessinsider.comHeron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026October 26, 2026 | globenewswire.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Stock Rated "Hold" by Sell-Side AnalystsOctober 25, 2026 | americanbankingnews.comSee More Heron Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Heron Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heron Therapeutics and other key companies, straight to your email. Email Address About Heron TherapeuticsHeron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy. Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings. The company continues to develop and commercialize therapies intended to improve patient care and reduce the burden associated with acute medical treatment.View Heron Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Are the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings BeatCheck Point's Turnaround Could Be Closer Than Investors ThinkTempus AI Surges on Earnings Beat, But Can the Rally Last?Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
